About
Theriva Biologics is a clinical-stage immuno-oncology company developing systemically deliverable oncolytic viruses engineered to selectively kill tumor cells and overcome barriers around solid tumors. Its therapies are intended to be combined with existing cancer treatments to improve outcomes for difficult-to-treat cancers.
Explore Theriva Biologics's full profile on Brouky
Funding rounds, investor list, and risk signals — unlock with a subscription.